Medical device company MediPines Corporation stated on Friday that it has received US FDA 510(k) clearance for the ground-breaking portable MediPines Gas Exchange Monitor respiratory device for freedivers to provide real-time, clinically actionable data in oxygen deficit.
The company added that freedivers place themselves in extreme conditions, which push the outer limits of human lung physiology and can lead to high oxygen deficit.
According to the company, the MediPines Gas Exchange Monitor device provided rapid feedback to the research team tasked with assessing the freedivers' gas exchange status. The oxygen deficit was developed for detecting gas exchange inefficiency using a simple, non-invasive method. The physiological demands placed on the athletes are tremendous.
This breakthrough technology is transforming the approach to measuring pulmonary gas exchange in a wide variety of clinical settings, relevant for the 33 million patients in the US (350m globally), who suffer from respiratory disease, disclosed the company.
Additionally, the novel physiologic results on world elite freedivers' using the company' non-invasive MediPines Gas Exchange Monitor were presented at the Experimental Biology 2019 conference. Dr Philip Ainslie, co-director of the Centre for Heart, Lung and Vascular Health at the University of British Columbia, conducted the study in Split, Croatia.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial